Quantcast
Last updated on April 23, 2014 at 11:40 EDT

Latest placebo Stories

2014-03-22 08:21:21

- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2) EAST HANOVER, N.J., March 22, 2014 /PRNewswire/ -- Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response...

Multiple Sclerosis May Benefit From Statins
2014-03-19 10:09:06

Brett Smith for redOrbit.com - Your Universe Online At first, multiple sclerosis is recognized by sporadic neurological symptoms – a condition called relapsing-remitting MS. Within a decade or so, greater than 50 percent of patients acquire secondary progressive MS, a continuous deterioration of symptoms and boost in disability. Currently, there are no approved drugs for treating this later stage of the disease. However, a newly published study in the UK medical journal The Lancet has...

2014-03-13 17:18:53

Investigators call on drug regulators to provide clear evidence to patients on claims of drug side effects At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them. Almost all the side effects reported in these trials "occurred anyway when patients...

Are Your Pets Benefiting From Their Pain Medication?
2014-03-13 15:17:15

Tracey Peake, North Carolina State University How do you know that your pet is benefiting from its pain medication? A new clinical trial design could help overcome pet owners’ unconscious observation bias and determine whether the drugs they test are effective. When animals are recruited for clinical trials, particularly for pain medications, researchers must rely on owner observation to determine whether the medication is working. Sounds simple enough, but as it turns out, human and...

2014-03-03 08:31:20

6.8% improvement in FEV1 versus placebo in high FENO subset representing half of treated patients BOULDER, Colo., March 3, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) reported full results from a randomized Phase 2 trial of ARRY-502 in patients with mild to moderate Th2-Driven Asthma at the 2014 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO ARRY-502, an oral CRTh2 antagonist, was studied in a...

2014-02-26 08:27:36

More information at: http://thesynergytrial.org MILL VALLEY, Calif., Feb. 26, 2014 /PRNewswire/ -- K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic...

2014-02-24 08:27:59

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in San Diego CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined...

2014-02-18 08:29:35

MELBOURNE, Australia and NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Key Points: -- Primary endpoints of safety and tolerability met. -- Secondary endpoint: Statistically significant improvement in a measure of executive function(cognition) in research participants administered 250mg PBT2 daily (p=0.042). -- PBT2 250mg was also associated with a favourable signal in functional capacity. -- Preliminary evidence suggests PBT2 250mg reduced atrophy of...

2014-02-14 23:01:28

Results from Alpha BRAIN™ Pilot Study to Be Presented at the International Neuropsychological Society Annual Conference Austin, Texas (PRWEB) February 14, 2014 Results from a pilot study entitled “A Proof of Concept Study for a Randomized Double-Blind, Placebo Controlled, Parallel Group, Efficacy Study of Alpha BRAIN™ Administered Orally,” conducted by the Boston Center for Memory will be presented at the annual International Neuropsychological Society (INS) meeting in Seattle,...

2014-02-11 23:28:04

Achieve is conducting a placebo-controlled, multicenter study to evaluate the blood pressure reduction with ambulatory blood pressure monitoring (ABPM), safety, and tolerability of a new drug in the treatment of subjects with hypertension and type 2 diabetes mellitus. Birmingham, AL (PRWEB) February 11, 2014 Achieve is conducting a placebo-controlled, multicenter study to evaluate the blood pressure reduction with ambulatory blood pressure monitoring (ABPM), safety, and tolerability of a...